Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

World Marrow Donor Day is significant as it highlights the crucial role that bone marrow and stem cell donors play in saving ...

Analyses of two large stem-cell transplant registries yielded conflicting results about the effect of post-transplant ...

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Researchers at Baylor College of Medicine, the University of Michigan and collaborating institutions have discovered that ...

The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

In addition to the physical challenges that Tom faced during his recovery period, individuals can also experience brain fog, ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...